Skip to main content

Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)

June 7, 2023

Topics Covered

We invite you to learn more about:

  • Treatment options for aggressive subtypes of non-Hodgkin lymphoma (NHL)
  • CAR T-cell therapy for aggressive lymphomas
  • Side-effects management
  • Questions to ask your healthcare team about treatment options and quality of life issues

Program Materials


Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas at MD Anderson Cancer Center
Houston, TX

Program Support

Support for this program is provided by Bristol Myers Squibb, Eli Lilly and Company, Genmab US & AbbVie Inc., Incyte Corporation, Kite, A Gilead Company, Merck & Company, and MorphoSys US.


< Back to Webcasts